

20 **Abstract**

21 **Background:** Molecular ageing clocks estimate an individual's biological age. Our aim was 22 to compare multiple machine learning algorithms for developing ageing clocks from nuclear 23 magnetic resonance (NMR) spectroscopy metabolomics data. To validate how well each 24 ageing clock predicted age-related morbidity and lifespan, we assessed their associations with 25 multiple health indicators (e.g., telomere length and frailty) and all-cause mortality. 26 **Methods:** The UK Biobank is a multicentre observational health study of middle-aged and 27 older adults. The Nightingale Health platform was used to quantify 168 circulating plasma 28 metabolites at the baseline assessment from 2006 to 2010. We trained and internally 29 validated 17 machine learning algorithms including regularised regression, kernel-based 30 methods and ensembles. Metabolomic age (MileAge) delta was defined as the difference 31 between predicted and chronological age. **Results:** The sample included 101,359 participants (mean age $= 56.53$ years, $SD = 8.10$). 33 Most metabolite levels varied by chronological age. The nested cross-validation mean 34 absolute error (MAE) ranged from 5.31 to 6.36 years. 31.76% of participants had an age-bias 35 adjusted MileAge more than one standard deviation (3.75 years) above or below the mean. A 36 Cubist rule-based regression model overall performed best at predicting health outcomes. The 37 all-cause mortality hazard ratio (HR) comparing individuals with a MileAge delta more than 38 one standard deviation above and below the mean was HR $= 1.52$ (95% CI 1.41-1.64, $p \lt \theta$) 39 0.001) over a median follow-up of 13.87 years. Individuals with an older MileAge were 40 frailer, had shorter telomeres, were more likely to have a chronic illness and rated their health 41 worse. 42 **Conclusions:** Metabolomic ageing clocks derived from multiple machine learning algorithms 43 were robustly associated with health indicators and mortality. Our metabolomic ageing clock 44 (MileAge) derived from a Cubist rule-based regression model can be incorporated in 45 research, and may find applications in health assessments, risk stratification and proactive 46 health tracking. 47 48 **Keywords:** ageing clocks; biological age; biomarkers; machine learning; metabolomics

49 **Introduction**

50 Chronological age, the time elapsed since birth, is a powerful predictor of health and disease

51 (Mutz, Roscoe, & Lewis, 2021). However, there is considerable heterogeneity in health

52 status, lifestyle and the physical signs of ageing between individuals of the same

53 chronological age. This variability may partly reflect individual differences in biological

54 ageing, which is the process of accumulating molecular and cellular damage that results in a

55 progressive decline in physiological functioning (Moqri et al., 2023). While our

56 chronological age cannot be altered, biological ageing trajectories in humans may be

57 modifiable, or even reversible. Therefore, developing reliable measures of biological age is

58 an important priority in biomedical research and population health.

59

60 Although there is no single biological marker of biological ageing, several hallmarks such as

61 telomere length shortening have been identified (López-Otín, Blasco, Partridge, Serrano, &

62 Kroemer, 2023). Clinical and population studies of age-related biological changes have also

63 examined physiological measures of grip strength and cardiovascular function (Mutz,

64 Hoppen, Fabbri, & Lewis, 2022; Mutz & Lewis, 2021; Mutz, Young, & Lewis, 2022), blood-

65 based biomarkers (Nakamura, Miyao, & Ozeki, 1988), inflammatory markers (Franceschi,

66 Garagnani, Parini, Giuliani, & Santoro, 2018) and frailty (Hoogendijk et al., 2019).

67

68 Molecular "omics" and neuroimaging data such as DNA methylation (Hannum et al., 2013;

69 Horvath & Raj, 2018; Lu et al., 2019) and structural magnetic resonance imaging (Cole &

70 Franke, 2017) have facilitated the development of biological ageing clocks (Rutledge, Oh, &

71 Wyss-Coray, 2022; Solovev, Shaposhnikov, & Moskalev, 2020). Ageing clocks are usually

72 developed using machine learning algorithms that identify relationships between

73 chronological age and molecular data. The difference between predicted age, which

74 approximates biological age, and chronological age is associated with health outcomes

75 (Macdonald-Dunlop et al., 2022). Ageing clocks provide a more holistic picture of a person's

76 health and are conceptually easier to understand than most individual molecular markers as

77 they are expressed in unit of years.

78

79 Population-scale metabolomics, the study of small molecules, i.e., metabolites, within cells,

80 tissues or organisms, is increasingly incorporated into biological ageing research (Panyard,

81 Yu, & Snyder, 2022). Metabolites are the products of metabolism, for example when food is

82 converted to energy. While many initial metabolomics studies were limited to few 83 metabolites and small samples, technological advancements have enabled the population-84 scale profiling of multiple molecular pathways (Soininen, Kangas, Würtz, Suna, & Ala-85 Korpela, 2015). Simultaneously quantifying hundreds or thousands of metabolites can 86 provide unprecedented snapshots of an individual's physiological state. Metabolomic profiles 87 predict many common incident diseases (Buergel et al., 2022) and mortality risk (Deelen et 88 al., 2019). Over the past decade, studies have characterised associations between 89 chronological age and metabolomic biomarkers (Lawton et al., 2008; Menni et al., 2013; Yu 90 et al., 2012). The first study to develop a "metabolite-derived age variable" showed that a 91 panel of 22 metabolites explained 59% of the variance in chronological age. A linear 92 combination of these metabolites was correlated with age-related clinical measures 93 independent of chronological age (Menni et al., 2013). The first study to develop a biological 94 ageing clock from metabolomics data showed that the difference between predicted and 95 chronological age, metabolomic age delta, was associated with a higher disease burden and 96 higher mortality (Hertel et al., 2016). Analyses in other samples, for example the Airwave 97 Health Monitoring Study in the UK (Robinson et al., 2020) and the Dutch BBMRI-NL 98 consortium (van den Akker et al., 2020), have since replicated some of these findings. 99 Metabolomics is amongst the most powerful omics data for biological age estimation 100 (Solovev et al., 2020) and prediction of disease (Macdonald-Dunlop et al., 2022). 101 102 The aim of this study was to compare multiple machine learning algorithms for developing 103 ageing clocks from nuclear magnetic resonance (NMR) spectroscopy metabolomics data in

104 more than 100,000 participants in the UK Biobank (Bycroft et al., 2018). These data provide 105 an unprecedented resource to develop ageing clocks and represent one of the largest single

-
- 106 NMR metabolomics databases to date. To validate how well each ageing clock predicted age-
- 107 related morbidity and lifespan, and captured biological signal beyond that approximated by
- 108 chronological age (Hertel et al., 2019), we assessed their associations with multiple health
- 109 indicators (e.g., telomere length and frailty) and all-cause mortality.

110 **Methods**

111 **Study population**

112 The UK Biobank is a prospective health study of over 500,000 UK residents aged 37–73 who

- 113 were recruited between 2006 and 2010. Individuals registered with the UK National Health
- 114 Service (NHS) and living within a 25-mile (~40 km) radius of one of 22 assessment centres
- 115 were invited to participate (Bycroft et al., 2018). Participants provided data on their
- 116 sociodemographic characteristics, health behaviours and medical history, underwent physical
- 117 examination and had blood and urine samples taken. There is extensive record linkage, for
- 118 example with national death registries, hospital inpatient records and primary care data.
- 119

120 **Metabolomic biomarker quantification**

121 Nuclear magnetic resonance (NMR) spectroscopy metabolomic biomarkers were quantified

- 122 in non-fasting blood plasma samples taken at the baseline assessment. The Nightingale
- 123 Health platform ascertains 168 circulating metabolites using a high-throughput standardized

124 protocol for sample quality control, preparation, data storage and automated analyses (Würtz

- 125 et al., 2017). The metabolites span multiple pathways, including lipoprotein lipids in 14
- 126 subclasses, circulating fatty acids and fatty acid compositions, as well as low-molecular
- 127 weight metabolites, such as amino acids, ketone bodies and glycolysis metabolites. Most
- 128 measures are highly correlated (*r* > 0.9) with routine clinical chemistry assays (Würtz et al.,
- 129 2017). For further details on sample preparation and quality control procedures, see
- 130 https://biobank.ndph.ox.ac.uk/ukb/ukb/docs/nmrm_companion_doc.pdf. We used the first
- 131 release of metabolomics data (March 2021) on a random subset of 118,019 participants.
- 132

133 **Machine learning**

- 134 We evaluated 17 machine learning algorithms, including regularised linear regression, latent
- 135 variable modelling, instance-based learning, non-parametric regression, kernel-based
- 136 methods, tree-based models, rule-based models and ensemble methods (Panel 1). To
- 137 internally validate each algorithm in predicting chronological age from plasma metabolites,
- 138 we implemented 10×5 nested cross-validation (Figure 1a). Nested cross-validation is
- 139 preferred for internal validation over other existing approaches as it provides more accurate
- 140 error estimation (Bates, Hastie, & Tibshirani). We split the data into 10 folds of equal size, to
- 141 which individuals were allocated at random while preserving the chronological age
- 142 distribution of the full analytical sample (Figure 1b).

211 | RuleFit ensemble: ensemble method that uses a tree-based model (XGBoost) to predict an 212 outcome and subsequently derives rules. LASSO is then used to select the most predictive 213 \parallel rules, resulting in a sparse linear model (J. H. Friedman & Popescu, 2008).

214

215 For each iteration of the outer loop of the nested cross-validation, 9/10 folds combined served 216 as the training set and the tenth fold served as the test set. The 90% training sets were further 217 divided into five equal size sets, and we performed 5-fold cross validation to empirically 218 identify, for each algorithm, the hyperparameter combination that resulted in the lowest 219 cross-validation mean absolute error (MAE). Tuning grids were set up using a maximum 220 entropy space-filling design. The size of each tuning grid was determined by the number of 221 available hyperparameters, type of hyperparameter (continuous, discrete or categorical) and 222 computational constraints. We tested up to ten values for each hyperparameter, resulting in 223 tuning grid sizes between ten (for Ridge regression) and 3125 (for XGBoost). Further details, 224 including pre-processing requirements, are available in Table S1. The model specifications 225 with the lowest 5-fold cross-validation MAE were subsequently fit in the 90% training sets, 226 and performance was assessed by calculating the MAE, root-mean-square error (RMSE), Pearson correlation coefficient (*r*) and the coefficient of determination (R^2) in the 10% test 228 sets. We also examined the average magnitude of discrepancy in predictive performance 229 between the training and test sets, extrapolation beyond the chronological age range in the

230 data and the computing hours required for hyperparameter tuning for each model.

231

232 **Metabolomic ageing clocks**

233 Individual-level age predictions for all participants were obtained by aggregating the

234 predictions of the ten test sets of the outer loop of the nested cross-validation. Metabolomic

235 age delta (MileAge delta) was calculated as the difference between predicted and

236 chronological age, with positive values representing an older predicted than chronological

237 age and negative values representing a younger predicted than chronological age. Given that

- 238 ageing clocks overestimate age in young individuals and underestimate age in older
- 239 individuals, we regressed predicted age (MileAge) on chronological age and used the
- 240 resulting intercept (β) and slope coefficient (α) estimates to apply a statistical correction to
- 241 the age prediction: MileAge (age bias adjusted) = MileAge + [Age $(\alpha \times \text{Age} + \beta)$] (de

242 Lange & Cole, 2020).

243 **Health indicators and mortality**

244 We tested associations between MileAge delta (adj.) and multiple health indicators: having a 245 long-standing illness, disability or infirmity (yes/no), self-rated health ("poor", "fair", "good" 246 or "excellent") and overall health status (unhealthy/healthy) derived from 81 cancer and 443 247 non-cancer illnesses (Mutz & Lewis, 2022; Mutz et al., 2021). Next we examined 248 associations with the frailty phenotype and frailty index (Mutz, Choudhury, Zhao, & Dregan, 249 2022). The frailty phenotype summarises data on weight loss, exhaustion, physical activity, 250 walking speed and hand-grip strength. The frailty index was derived from 49 variables 251 obtained at the baseline assessment, including cardiometabolic, cranial, immunological, 252 musculoskeletal, respiratory and sensory traits, well-being, infirmity, cancer and pain. We 253 also tested associations between MileAge delta (adj.) and telomere length, measured using a 254 validated quantitative polymerase chain reaction assay that expresses telomere length as the 255 ratio of the telomere repeat copy number (T) relative to a single-copy gene (S) that encodes 256 haemoglobin subunit beta. T/S ratio is proportional to an individual's average telomere length 257 (Lai, Wright, & Shay, 2018). Finally, we examined prospective associations with all-cause 258 mortality. The date of death was obtained through linkage with national death registries, NHS 259 Digital (England and Wales) and the NHS Central Register (Scotland). The censoring date 260 was 30 November 2022.

261

262 **Exclusion criteria**

263 Women who were pregnant or unsure that they were pregnant at the time of assessment were 264 excluded from the analysis given that their metabolite profiles likely changed during 265 pregnancy. Participants for whom their genetic and self-reported sex did not match were also 266 excluded as this may indicate poor data quality. We also excluded individuals with missing 267 metabolite data or potential outlier metabolite values, defined as values $4\times$ the interquartile 268 range (IQR) above or below the median.

269

270 **Statistical analyses**

- 271 All data processing and analyses were performed in R (version 4.2).
- 272

273 Sample characteristics were summarised using means and standard deviations or counts and

- 274 percentages. Generalised additive models were used to explore the relationship between
- 275 chronological age and metabolite levels. We further conducted metabolome-wide association
- 276 analyses of chronological age and all-cause mortality to identify metabolites that were

277 statistically significantly associated with chronological age and mortality (at *P* < 0.05/168).

278 Correlations between the predicted age derived from each machine learning model were

- 279 estimated using Pearson's correlation coefficient.
- 280

281 Cross-sectional associations between MileAge delta (adj.) and the frailty index and telomere 282 length were estimated using ordinary least squares regression. Associations between MileAge 283 delta and having a long-standing illness and overall health status were estimated using 284 logistic regression. Association between MileAge delta and the frailty phenotype and self-285 rated health were estimated using ordinal logistic regression. For each health indicator, higher 286 values corresponded to worse health. For the health association analyses, we fitted minimally 287 adjusted models that included chronological age and sex as covariates. For the prospective 288 analyses of all-cause mortality, we calculated person-years of follow-up and the median 289 duration of follow-up of censored individuals. Survival probabilities by MileAge delta were 290 estimated using the Kaplan-Meier (KM) method (Kaplan & Meier, 1958) and we calculated 291 log-rank *p*-values. Hazard ratios (HRs) and 95% confidence intervals were estimated using 292 Cox proportional hazards models (Cox, 1972). Age in years was used as the underlying time 293 axis, with age 40 as the start of follow-up. Across both cross-sectional and prospective 294 analyses, we defined MileAge delta subgroups by standard deviation from the mean. 295 Individuals with a MileAge delta equal to or smaller than one standard deviation below the 296 mean were the reference group. To discern how this analytical decision might impact results, 297 and to enable comparability with other studies, we also report associations with all-cause 298 mortality for all models with subgroups defined by the bottom and top 10% of the 299 distribution as well as negative and positive values. Finally, we used generalised additive 300 models and spline functions to explore the relationship between MileAge delta as a 301 continuous variable and health indicators and all-cause mortality, respectively. 302

303 For the Cubist rule-based regression model, which across most analyses performed best at 304 predicting health outcomes, we performed additional analyses. We calculated variable 305 importance scores to identify metabolites that strongly contributed to MileAge. We explored 306 associations between MileAge delta and all-cause mortality stratified by sex, self-rated health 307 and chronological age group (39-49, 50-59 and 60-71 years). Finally, we assessed the 308 performance of our ageing clock by benchmarking it against other ageing markers: (a) we 309 estimated the hazard ratio for all-cause mortality by MileAge delta and other ageing marker 310 (grip strength, telomere length and the frailty index) subgroups defined by standard deviation

- 311 from the mean, adjusted for chronological age and sex; (b) we calculated the C-index and
- 312 95% confidence intervals for chronological age + sex (as the base model) and for each ageing
- 313 marker added separately to the model, with time (in days) since the baseline assessment as
- 314 the underlying time axis.

315 **Results**

316 **Sample characteristics**

- 317 Of the 118,019 participants with metabolomics data, 110,730 had complete information on all
- 318 metabolites (Figure S1). After removing individuals with potential outlier metabolite values,
- 319 inconsistencies between self-reported and genetic sex or possible pregnancies, the analytical
- 320 sample included 101,359 participants (Table 1). The mean chronological age was 56.44 years
- 321 (SD = 8.12), with the most common age being 61 years (Figure 1b). Most metabolite levels
- 322 varied by chronological age (Figure 1c), showing considerable evidence of non-linear
- 323 relationships (Figures S2-S33).
- 324

Table 1. Sample characteristics

Note: GCSEs = general certificate of secondary education; CSE = certificate of secondary education; $NVO =$ national vocational qualification; $HND =$ higher national diploma; $HNC =$ higher national certificate. MileAge delta (adj.) derived from the Cubist rule-based regression model. ¹Missing data may also include "do not know", "prefer not to answer", "not applicable" or related responses. ²Also includes 'other professional qualifications'. ³Annual household income groups: very low (<£18,000), low (£18,000–£30,999), middle (£31,000–£51,999), high $(£52,000–£100,000)$ and very high (>£100,000). $n = 59519$ females. $n = 3$ missing. $n = 345$ missing.

325

326 **Metabolite-wide associations**

- 327 165/168 metabolites were associated with chronological age (*p* < 0.05/168). While most
- 328 metabolite levels were elevated in older individuals (e.g., Omega 3, citrate and glucose),
- 329 seven, including albumin, glycine and histidine, were negatively associated with
- 330 chronological age (Figure S34; Additional file 1). Amongst the 119 metabolites associated
- 331 with all-cause mortality, GlycA was most strongly associated with a higher mortality hazard
- 332 (HR = 1.22, 95% CI 1.20-1.25, *p* < 0.001), whereas the degree of unsaturation,
- 333 docosahexaenoic acid (DHA) and Omega 3 were strongly associated with a lower mortality
- 334 hazard (Figure S35; Additional file 2). Notably, 116 metabolites associated with
- 335 chronological age also predicted mortality, with GlycA, Omega 3 and DHA amongst the
- 336 most strongly associated metabolites of both age and mortality (Figure 1d). Between 87%
- 337 and 95% of the metabolites that were statistically significantly associated with other health
- 338 indicators (e.g., frailty and health status) were associated with chronological age (Figure
- 339 S36). The exception was telomere length for which only 53% of statistically significant
- 340 metabolites were shared with chronological age.

341

342 **Predictive model performance**

343 Predictive performance estimates in the 90% training (*n* = 91,222 to 91,226) and 10% test 344 sets are shown in Table S3. The nested cross-validation mean absolute error (MAE) in the 345 test sets $(n = 10,133)$ to 10,137) ranged from 5.31 to 6.36 years, with the support vector 346 regression with a radial basis function (SVM radial) performing best and the MARS 347 ensemble performing worst. The root-mean-square error (RMSE) ranged from 6.60 to 7.58 348 years. Correlation coefficients between predicted and chronological age ranged from 0.36 to 349 0.59, with R^2 values between 0.13 and 0.35. The difference in predictive performance 350 between the training and test sets, i.e., the model's optimism which may indicate poor 351 generalization to unseen data, was generally low (e.g., MAEdifference < 0.15 for 10/17 models). 352 However, certain tree-based models (bagging, random forest and XGBoost) and the *k*-nearest 353 neighbors model overfit the training data ($MAE_{difference} = -1.51$ to -5.83), with correlation 354 coefficients between predicted and chronological age of $r > 0.8$ in the training sets (Figure 355 S40). Figure 2a shows the nested cross-validation MAEs for all models. For comparison, 356 drawing random samples from a uniform distribution between the sample's minimum and 357 maximum chronological age, i.e., a random prediction model, resulted in a MAE = 9.79. 358 Predicting the sample mean, i.e., a null model, resulted in a MAE = 6.96. Additional plots 359 showing other performance measures (MAE, RMSE, *r* and R^2) in the training and test sets are 360 presented in the supplement (Figures S37-S43). There were moderate to high correlations 361 between the predicted age values of the various models $(r = 0.48$ to $> 0.99)$ (Figure 2b). High 362 correlations $(r > 0.87)$ amongst the most accurate models suggest they capture similar 363 patterns in the data. Omega 3, albumin and citrate were amongst the most important 364 contributors to predictive accuracy (Figure S44).

365

366 **Age bias correction**

367 All models overestimated the age of young individuals and underestimated the age of older 368 individuals (Figure S44). Applying a statistical correction (see Methods) to the predicted age 369 values removed this bias (Figures 2c-e and S45). The predicted age values were originally 370 within the chronological age range (39 to 70 years) of the sample for most individuals.

- 371 Across *all* models, 0.23% (*n* = 238) and 0.96% (*n* = 976) of predictions were below or above
- 372 the minimum and maximum age, respectively (Table S4). More predicted age values were
- 373 outside the chronological age range (up to 8.27%, *n* = 8382 for a single model) after the age
- 374 bias correction. Re-calculating the predictive performance estimates after the age bias

375 correction suggested higher accuracy (MAE = 2.12 to 3.40; Figure 2f). The overall

376 performance rankings across the models inverted, with the models that originally predicted

377 chronological age best showing reduced accuracy (Figures S46-S48). The age bias adjusted

378 MileAge delta ranged from -18.94 years younger to 16.05 years older for the Cubist rule-

- 379 based regression model, with 15.99% (*n* = 16,204) and 15.77% (*n* = 15,989) of the sample
- 380 having a MileAge delta (adj.) of at least 3.75 years below or above the mean (Figure 2g;
- 381 Table S5).
- 382

383 **Associations with health indicators**

384 Descriptive statistics for the health indicators are shown in Table S6. Having an older 385 predicted than chronological age was associated with higher frailty index scores across all

- 386 models (Table S7). This extended to the frailty phenotype for all models when comparing
- 387 individuals with a MileAge delta (adj.) more than one standard deviation above and below
-
- 388 the mean, and for 12/17 models when comparing the middle of the distribution to individuals
- 389 with MileAge delta (adj.) values more than one standard deviation below the mean (Table
- 390 S8). For telomere length, we observed a group difference for 12/17 models when comparing
- 391 the tails of the distribution, and for 9/17 models when comparing the middle of the
- 392 distribution to the reference group (Table S9). Having an older predicted than chronological
- 393 age was generally associated with chronic illness and poor self-rated health (Tables S10-
- 394 S12). An exception to this pattern were the MARS models, for which an older predicted than
- 395 chronological age was associated with *longer* telomeres, and for which there was little
- 396 evidence of statistically significant differences in health between individuals with MileAge
- 397 delta (adj.) values in the middle of the distribution and the reference group.
- 398
- 399 MileAge delta (adj.) derived from the Cubist rule-based regression model was most strongly
- 400 associated with most health indicators (Figure 3a). Individuals with a MileAge delta (adj.)

401 greater than one standard deviation above the mean had higher frailty index scores than

- 402 individuals with a MileAge delta (adj.) smaller than one standard deviation below the mean
- 403 (β = 0.023, 95% CI 0.021–0.024, *p* < 0.001). This group difference was approximately
- 404 equivalent to an 18.3-year chronological age difference in frailty index scores ($\beta = 0.023$)
- 405 divided by $\beta = 0.001255$ derived from a linear model, y $_{\text{frailty index}} \sim x$ chronological age).
- 406 Individuals with an older predicted than chronological age were also more likely to be
- 407 physically frail (OR = 1.29, 95% CI 1.23–1.35, $p < 0.001$) and had shorter telomeres (β =
- 408 0.052, 95% CI 0.030 to 0.073, *p* < 0.001) equivalent to a 2.2-year chronological age

409 difference in telomere length. Such individuals were also more likely to have a long-standing 410 illness (OR = 1.82, 95% CI 1.73–1.91, *p* < 0.001), poorer health status (OR = 1.85, 95% CI 411 1.76–1.94, *p* < 0.001) and worse self-rated health (OR = 1.72, 95% CI 1.65–1.80, *p* < 0.001). 412 Generalised additive models showed that positive MileAge delta (adj.) values, indicating 413 accelerated biological ageing, were robustly associated with unfavourable health (Figure 3b), 414 whereas negative MileAge delta (adj.) values were only weakly associated with favourable 415 health, a pattern that was consistent across most models (Figures S49-S54). 416 417 **Predicting mortality** 418 The median duration of follow-up of censored individuals was 13.87 years (IQR = 1.37 419 years), with 1,361,970 person-years of follow-up. There were 8113 deaths amongst 101,274 420 participants ($n = 85$ missing). MileAge (adj.) was strongly associated with all-cause 421 mortality, comparable to chronological age (Figures 4a-e). In the prospective analyses we 422 examined the age bias adjusted MileAge delta and models were adjusted for chronological 423 age and sex, with age (in years) as the underlying time axis (Figure S55 and Table S13).

424

425 For the Cubist rule-based regression model, the hazard ratio (HR) comparing individuals with 426 a MileAge delta (adj.) greater than one standard deviation above and below the mean was HR $427 = 1.52 (95\% \text{ CI } 1.41 - 1.64, p < 0.001)$. Individuals with a MileAge delta (adj.) between one

428 standard deviation above and below the mean had a statistically significantly higher mortality

429 risk for 14/17 models (*p* between 0.03 and < 0.001) (Table S14). Comparing the bottom and 430 top 10% of the MileAge delta (adj.) distribution, instead of one standard deviation above and

431 below the mean, resulted in greater differences (e.g., $HR = 1.63$, 95% CI 1.48-1.79, $p < 0.001$

- 432 for the Cubist model). Individuals in between the tails of the distribution had a higher
- 433 mortality risk compared to the bottom 10% for 14/17 models (Figure S56 and Table S15).
- 434 When comparing individuals with a positive and negative MileAge delta (adj.), we found that
- 435 individuals with an older predicted than chronological age had a higher mortality risk for all

436 models except the MARS models (Figure S57 and Table S16). Modelling the mortality

437 hazard as a spline function of MileAge delta (adj.) suggested that positive values were

438 strongly associated with a higher mortality hazard, while there was little evidence that

439 negative values were associated with a lower mortality hazard (Figure S58).

440

441 Females had slightly higher MileAge delta (adj.) values than males (Figure 4f), a pattern

442 which we observed across all models (Figure S59). The mortality hazard of individuals with a

- 453 50 years (Figures S62 and 4h; Table S17).
- 454

455 **Comparison with other ageing markers**

456 A comparison of the all-cause mortality hazard associated with MileAge delta (adj.) and

457 other ageing marker subgroups defined by the standard deviation from the mean showed that

458 the largest hazard ratio (HR = 2.90) was observed for the frailty index (Figure 5a). The

459 smallest hazard ratio was observed for telomere length ($HR = 1.31$) (Table S18), with

460 MileAge delta (adj.) (HR = 1.52) and grip strength (HR = 1.90) in-between. Adding each

461 ageing marker individually as a continuous variable to a base model that included

462 chronological age and sex improved prediction of all-cause mortality, with the best prediction

463 observed for the frailty index (C-index 0.737, 95% CI 0.732 to 0.742 vs C-index 0.716, 95%

464 CI 0.711 to 0.722 for the base model) (Figure 5b and Table S19). Modelling the mortality

465 hazard as a spline function of the ageing markers, to identify potential non-linear effects,

466 suggested that the all-cause mortality hazard was considerably higher in individuals with an

- 467 older predicted than chronological age. For example, compared to the sample median
- 468 MileAge delta (adj.), which was equivalent to no difference between predicted and
- 469 chronological age, a MileAge delta (adj.) of 10 was associated with a HR of about 2.7, i.e., a
- 470 170% higher morality hazard (Figure 5c).

471 **Discussion**

472 In 101,359 UK Biobank participants with Nightingale Health metabolomics data, we 473 observed that most metabolite levels varied by chronological age, with considerable evidence 474 of non-linear associations. Across the machine learning algorithms employed to develop 475 ageing clocks from circulating plasma metabolites, the nested cross-validation mean absolute 476 error between predicted age (MileAge) and chronological age ranged from 5.31 to 6.36 years $(377 \text{ } (R^2)$ between 0.13 and 0.35). All models overestimated age in young individuals and 478 underestimated age in older individuals. After applying a statistical correction to remove this 479 age bias, 31.76% of participants had adjusted MileAge delta values of at least 3.75 years, 480 highlighting the potential of metabolomic ageing clocks to differentiate between individuals 481 of the same chronological age (Hertel et al., 2019). While there was a high degree of 482 consistency across the top performing models such as support vector regression, tree-based 483 and rule-based ensembles, the ageing clock derived from a Cubist rule-based regression 484 model (MAE = 5.42) was most strongly associated with most health indicators. We observed 485 across most models that individuals with an older predicted than chronological age, 486 indicating accelerated biological ageing, were frailer, had shorter telomeres, were more likely 487 to have a chronic illness, rated their health worse and had a higher mortality risk.

488

489 Multiple studies have developed biological ageing clocks trained on chronological age from 490 metabolomics data. The seminal study by Menni et al. (2013) derived a metabolite age score 491 as a linear combination of 22 plasma metabolites that were correlated with chronological age 492 in 6055 twins, achieving an R^2 of 59% and a hazard ratio for all-cause mortality of HR = 1.08 493 per year. Hertel et al. (2016) tested a multivariable linear regression and a fractional 494 polynomial model in 3611 participants, with the latter achieving a correlation between 495 predicted and chronological age of $r = 0.53$ (RMSE = 11.19) in men and $r = 0.61$ (RMSE = 496 10.37) in women. Their metabolomic ageing clock included 59 urinary metabolites and was 497 predictive of all-cause mortality (HR = 1.24 per SD). Robinson et al. (2020) developed 498 several ageing clocks using elastic net models in 2238 participants, with correlations between 499 predicted and chronological age of $r = 0.45$ (MAE $= 4.17$) to $r = 0.83$ (MAE $= 6.49$). Akker 500 et al. (2020) developed an ageing clock, MetaboAge, from 56 metabolites in 18,716 501 participants from 24 community and hospital-based cohorts using a linear regression model, 502 achieving a correlation of $r = 0.65$ and a median absolute error of 7.3. An independent 503 external validation of this clock observed a notably lower correlation of *r* = 0.21 (Macdonald-

504 Dunlop et al., 2022). The same study also developed a clock from NMR metabolomics data 505 (81/86 metabolites selected) in 1643 individuals, which achieved a correlation of *r* = 0.74 but 506 failed to replicate in a validation cohort, and another clock from mass spectrometry 507 metabolomics (181/682 metabolites selected) in 861 individuals, which achieved a

508 correlation of $r = 0.81$ (Macdonald-Dunlop et al., 2022). An updated ageing clock,

MetaboAge 2.0, in the BBMRI-nl data that included 65 metabolites achieved an R^2 of 0.451

- 510 and 0.449 for a linear regression and elastic net model, respectively (Bizzarri et al., 2023).
- 511

512 Metabolomic ageing clocks trained on chronological age are generally less accurate than

513 ageing clocks derived from other types of omics data (Rutledge et al., 2022). Nevertheless,

514 our most predictive model (MAE = 5.31 years) had a similar accuracy as a deep learning

515 ageing clock (MAE = 5.68) derived from blood markers, biometrics and sex in the China

516 Health and Retirement Longitudinal Study. An elastic net model in the same data achieved a

517 MAE = 6.19 years (Galkin et al., 2022), while the elastic net model in our study had a lower

518 MAE = 5.70, likely due to the larger sample size. While a discussion of how well different

519 ageing clocks predict health outcomes is beyond the scope of this study, the most widely

520 tested epigenetic ageing clocks that were trained on chronological age are weak predictors of

521 mortality (B. H. Chen et al., 2016; Fransquet, Wrigglesworth, Woods, Ernst, & Ryan, 2019).

522 Second-generation ageing clocks are more predictive of mortality. For example, a one-year

523 increase in PhenoAge, which was trained on physiological dysregulation, was associated with

524 a 9% increase in mortality risk. Its epigenetic derivation, DNAm PhenoAge, was associated

525 with a 4.5% increase in all-cause mortality (Levine et al., 2018). GrimAge, another popular

526 mortality risk predictor that incorporates chronological age, sex and eight DNA methylation

527 surrogate markers (seven for plasma proteins and one for smoking pack-years) strongly

528 predicts mortality and age-related diseases (Lu et al., 2019). A recent clock developed from

529 circulating biomarkers and trained to predict mortality in the UK Biobank (*n* = 307,000)

530 using an elastic net Cox model (Bortz et al., 2023) yielded a 9.2% relative increase in

531 prediction compared to the PhenoAge model. However, the improvement in prediction over a

532 model that included chronological age and sex was modest (C-index 0.715 vs 0.762,

533 compared to 0.716 vs 0.719 in our study; though note that our clock was not trained to predict

534 mortality). These findings suggest that certain omics clocks capture physiologically relevant

535 signals more, while first-generation epigenetic clocks are specifically good at predicting

536 chronological time (Rutledge et al., 2022).

537

538 Although chronological age prediction is valuable in fields such as forensics (Vidaki et al., 539 2017), it is of limited use in population health and geroscience, given that chronological age 540 is non-modifiable (Robinson & Lau, 2020). A perfect prediction model would merely tell us 541 about chronological, not biological, age (Nakamura et al., 1988). It is the *difference* between 542 predicted and chronological age (MileAge delta) that serves as an indicator of accelerated or 543 decelerated ageing. A less accurate chronological age prediction does not necessarily indicate 544 a worse biological age model (Hertel et al., 2019), hence we also tested algorithms that were 545 expected to perform less well at predicting chronological age (e.g., bagging). Prior studies 546 suggested that biological age estimates derived from physical activity (Pyrkov et al., 2018) or 547 epigenetic data (Zhang et al., 2019) with higher predictive accuracy of chronological age 548 were less predictive of all-cause mortality. Our study showed that the models that were most 549 predictive of chronological age were generally also more strongly associated with health and 550 mortality, though we note that the pattern of predictive accuracy largely inverted after we 551 applied the age bias correction.

552

553 We report several additional analyses, including variable importance scores and 554 benchmarking against other ageing markers, for the ageing clock derived from the Cubist 555 rule-based regression model, which was most strongly associated with most health indicators. 556 There are, however, several conclusions that can be drawn across most of the machine 557 learning algorithms tested. First, the wide range of the MileAge delta values quantifies the 558 latent patterns in the metabolomics data not captured by chronological age and suggests that 559 our ageing clocks approximate (past) rate of biological ageing for people of the same 560 chronological age. Second, the associations between most ageing clocks, health and mortality 561 demonstrate that these clocks capture biologically relevant information, which may find 562 applications in health tracking, nutrition or in clinical trials (e.g., sample stratification). A key 563 finding across most ageing clock models tested here was that associations with health and 564 mortality were stronger in individuals with an older predicted than chronological age and less 565 so in individuals with a younger predicted than chronological age.

566

567 Several of the algorithms included in our comparison, including those that were most

568 predictive of chronological age, mortality and health, allowed for non-linear relationships in

569 the data, which were often not considered in previous studies (Panyard et al., 2022). A recent

570 review found that most molecular ageing clocks were developed using linear models with

571 regularization, whereas few used non-linear models (Xia, Wang, Yu, Chen, & Han, 2021).

20

572 Although it has been asserted that age-related physiological markers are linearly associated 573 with age (Pyrkov et al., 2018), we have shown here and in previous studies (Mutz, Hoppen, et 574 al., 2022; Mutz & Lewis, 2021; Mutz, Young, et al., 2022) that this does not apply to many 575 biological markers. To enable comparability between studies, we provide a comprehensive 576 set of statistical estimates and developed our ageing clock using metabolites measured in 577 absolute concentrations instead of relative to other measures. Although it may be argued that 578 quantification of a smaller number of metabolites would in principle be more feasible and 579 convenient in clinical practice, all metabolites included in our model can be quantified from a 580 single assay with minimal sample preparation required (Würtz et al., 2017).

581

582 **Limitations and future directions**

583 Our study had certain limitations. Some algorithms that have previously been used to develop 584 biological ageing clocks, for example deep learning (Zhavoronkov, Li, Ma, & Mamoshina, 585 2019), or approaches combining HSIC LASSO feature selection with non-linear support 586 vector regression (Takahashi et al., 2020) were not tested, and could be explored in future 587 studies. Our ageing clock provides a "systems level" indicator of age-related changes in 588 metabolites; future clocks may be developed at the tissue or cellular level. Plasma samples 589 may differ from other body fluids, e.g., serum, urine or cerebrospinal fluid. The metabolite 590 coverage of the Nightingale Health platform is lipid focussed and mostly covers larger 591 molecules, while there are potentially over 217,000 endogenous and exogenous molecules 592 (Wishart et al., 2021). Nevertheless, this platform enables robust assessment of these 593 metabolites in a single experiment (Würtz et al., 2017). Although more complex ageing 594 clocks could be developed using technologies with wider metabolite coverage, prior analyses 595 suggested that a majority of metabolites associated with age were related to lipid and amino 596 acid pathways, both of which were included here (Menni et al., 2013). As in previous studies, 597 we observed a systematic overestimation of age in young individuals and underestimation of 598 age in older individuals (Nakamura et al., 1988). This bias is neither data nor method specific 599 and may be explained by regression to the mean (Liang, Zhang, & Niu, 2019) of the training 600 data (Jones, Lee, & Topol, 2022). To account for this bias, we have adjusted the predicted 601 age and included chronological age as a covariate in the health association analyses (Xia et 602 al., 2021). Longitudinal ageing metrics may be more robustly associated with certain health 603 outcomes than cross-sectional ageing metrics, e.g., with physical and cognitive decline but 604 not, for example, multimorbidity (Kuo et al., 2022). Future research should develop

605 metabolomic ageing clocks from longitudinal data. Finally, the lack of independent data for 606 external validation is a limitation.

607

608 **Conclusions**

- 609 Metabolomic ageing clocks derived from multiple machine learning algorithms were robustly
- 610 associated with health indicators and mortality. We found that our ageing clock (MileAge)
- 611 derived from a Cubist rule-based regression model was overall most strongly associated with
- 612 health indicators. Individuals with MileAge values greater than their chronological age,
- 613 indicating accelerated biological ageing, were frailer, had shorter telomeres, were more likely
- 614 to have a chronic illness, rated their health worse and had a higher mortality risk.
- 615 Metabolomic ageing clocks hold significant promise for research on lifespan and healthspan
- 616 extension, as they provide a proxy of biological ageing that is potentially modifiable. These
- 617 clocks may also help identify health risks before clinical symptoms emerge. As such,
- 618 biological ageing clocks may contribute to health risk assessments, complementing clinical
- 619 biomarkers. However, the utility of ageing clocks is not limited to risk stratification, but also
- 620 in providing an intuitive, year-based metric for health tracking that may help individuals
- 621 proactively engage with their health.

622 **Acknowledgments**

- 623 This research is funded by the National Institute for Health and Care Research (NIHR)
- 624 Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation
- 625 Trust and King's College London. The views expressed are those of the authors and not
- 626 necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
- 627 Computational analyses were supported by: King's College London. (2023). King's
- 628 Computational Research, Engineering and Technology Environment (CREATE). Retrieved
- 629 May 24, 2023, from https://doi.org/10.18742/rnvf-m076. This research has been conducted
- 630 using data from UK Biobank, a major biomedical database. Data access permission has been
- 631 granted under UK Biobank application 45514.
- 632

633 **Financial disclosures**

- 634 CML is a member of the scientific advisory board of Myriad Neuroscience, has received
- 635 speaker fees from SYNLAB and received consultancy fees from UCB. JM and RI declare no
- 636 financial conflict of interest.
- 637

638 **Authorship contributions**

- 639 JM conceived the idea of the study, acquired the data, carried out the analysis, interpreted the
- 640 findings and wrote the manuscript. CML and RI interpreted the findings and reviewed the
- 641 manuscript. All authors read and approved the final manuscript.
- 642

643 **Ethics**

- 644 Ethical approval for the UK Biobank study has been granted by the National Information
- 645 Governance Board for Health and Social Care and the NHS North West Multicentre Research
- 646 Ethics Committee (11/NW/0382). No project-specific ethical approval is needed.
- 647

648 **Data sharing statement**

- 649 The data used are available to all *bona fide* researchers for health-related research that is in
- 650 the public interest, subject to an application process and approval criteria. Study materials are
- 651 publicly available online at http://www.ukbiobank.ac.uk.
- 652

653 **Supplementary material**

654 Supplementary information is available online.

655 **References**

656 657 Akker, E. B. v. d., Trompet, S., Wolf, J. J. H. B., Beekman, M., Suchiman, H. E. D., Deelen, 658 J., . . . Slagboom, P. E. (2020). Metabolic Age Based on the BBMRI-NL 1H-NMR 659 Metabolomics Repository as Biomarker of Age-related Disease. *Circulation:* 660 *Genomic and Precision Medicine, 13*(5), 541-547. 661 doi:doi:10.1161/CIRCGEN.119.002610 662 Bates, S., Hastie, T., & Tibshirani, R. Cross-Validation: What Does It Estimate and How 663 Well Does It Do It? *Journal of the American Statistical Association*, 1-12. 664 doi:10.1080/01621459.2023.2197686 665 Bizzarri, D., Reinders, M. J. T., Beekman, M., BBMRI-NL, Slagboom, P. E., & Akker, E. B. 666 v. d. (2023). Technical report: A comprehensive comparison between different 667 quantification versions of Nightingale Health's 1H-NMR metabolomics platform. 668 *medRxiv*, 2023.2007.2003.23292168. doi:10.1101/2023.07.03.23292168 669 Bortz, J., Guariglia, A., Klaric, L., Tang, D., Ward, P., Geer, M., . . . Joshi, P. K. (2023). 670 Biological Age Estimation Using Circulating Blood Biomarkers. *medRxiv*, 671 2023.2002.2023.23285864. doi:10.1101/2023.02.23.23285864 672 Boser, B. E., Guyon, I. M., & Vapnik, V. N. (1992). *A training algorithm for optimal margin* 673 *classifiers*. Paper presented at the Proceedings of the fifth annual workshop on 674 Computational learning theory, Pittsburgh, Pennsylvania, USA. 675 https://doi.org/10.1145/130385.130401 676 Breiman, L. (1996). Bagging predictors. *Machine Learning, 24*(2), 123-140. 677 doi:10.1007/BF00058655 678 Breiman, L. (2001). Random Forests. *Machine Learning, 45*(1), 5-32. 679 doi:10.1023/A:1010933404324 680 Breiman, L., Friedman, J., Olshen, R., & Stone, C. (1984). Classification and Regression 681 Trees. 682 Buergel, T., Steinfeldt, J., Ruyoga, G., Pietzner, M., Bizzarri, D., Vojinovic, D., . . . 683 Landmesser, U. (2022). Metabolomic profiles predict individual multidisease 684 outcomes. *Nature Medicine, 28*(11), 2309-2320. doi:10.1038/s41591-022-01980-3 685 Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., . . . O'Connell, J. 686 (2018). The UK Biobank resource with deep phenotyping and genomic data. *Nature,* 687 *562*(7726), 203-209. doi:https://doi.org/10.1038/s41586-018-0579-z

688 Chen, B. H., Marioni, R. E., Colicino, E., Peters, M. J., Ward-Caviness, C. K., Tsai, P. C., . . .

689 Horvath, S. (2016). DNA methylation-based measures of biological age: meta-690 analysis predicting time to death. *Aging (Albany NY), 8*(9), 1844-1865. 691 doi:10.18632/aging.101020 692 Chen, T., & Guestrin, C. (2016). *XGBoost: A Scalable Tree Boosting System*. Paper presented 693 at the Proceedings of the 22nd ACM SIGKDD International Conference on 694 Knowledge Discovery and Data Mining, San Francisco, California, USA. 695 https://doi.org/10.1145/2939672.2939785 696 Chipman, H. A., George, E. I., & McCulloch, R. E. (2010). BART: Bayesian additive 697 regression trees. *The Annals of Applied Statistics, 4*(1), 266-298, 233. Retrieved from 698 https://doi.org/10.1214/09-AOAS285 699 Cole, J. H., & Franke, K. (2017). Predicting Age Using Neuroimaging: Innovative Brain 700 Ageing Biomarkers. *Trends in Neurosciences, 40*(12), 681-690. 701 doi:https://doi.org/10.1016/j.tins.2017.10.001 702 Cover, T., & Hart, P. (1967). Nearest neighbor pattern classification. *IEEE Transactions on* 703 *Information Theory, 13*(1), 21-27. doi:10.1109/TIT.1967.1053964 704 Cox, D. R. (1972). Regression models and life□tables. *Journal of the Royal Statistical Society: Series B (Methodological), 34(2), 187-202.* 705 *Society: Series B (Methodological), 34*(2), 187-202. 706 de Lange, A. G., & Cole, J. H. (2020). Commentary: Correction procedures in brain-age 707 prediction. *Neuroimage Clin, 26*, 102229. doi:10.1016/j.nicl.2020.102229 708 Deelen, J., Kettunen, J., Fischer, K., van der Spek, A., Trompet, S., Kastenmüller, G., . . . 709 Slagboom, P. E. (2019). A metabolic profile of all-cause mortality risk identified in an 710 observational study of 44,168 individuals. *Nature Communications, 10*(1), 3346. 711 doi:10.1038/s41467-019-11311-9 712 Drucker, H., Burges, C. J., Kaufman, L., Smola, A., & Vapnik, V. (1996). Support Vector 713 Regression Machines. *Advances in neural information processing systems, 9*. 714 Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., & Santoro, A. (2018). Inflammaging: a 715 new immune–metabolic viewpoint for age-related diseases. *Nature Reviews* 716 *Endocrinology, 14*(10), 576-590. doi:10.1038/s41574-018-0059-4 717 Fransquet, P. D., Wrigglesworth, J., Woods, R. L., Ernst, M. E., & Ryan, J. (2019). The 718 epigenetic clock as a predictor of disease and mortality risk: a systematic review and 719 meta-analysis. *Clinical Epigenetics, 11*(1), 62. doi:10.1186/s13148-019-0656-7 720 Friedman, J., H. (1991). Multivariate Adaptive Regression Splines. *The Annals of Statistics,* 721 *19*(1), 1-67. doi:10.1214/aos/1176347963

28

Figure 1. a, Overview of the nested cross-validation approach. MAE = mean absolute error; RMSE = rootmean-square error. **b,** Histogram of the chronological age distribution of the full analytical sample. The statistical mode (age = 61 years) is shown in red. **c,** Distribution of metabolite levels by chronological age, showing scatter plots of all observations and smooth curves (note the difference in y-axis scale). The smooth curves were estimated using generalised additive models, with shaded areas corresponding to 95% confidence intervals. GlycA = glycoprotein acetyls. **d**, Scatter plot showing the hazard ratio (HR) for allcause mortality and the beta for chronological age associated with a one standard deviation (SD) difference in metabolite levels. Metabolites that had statistically significant associations with both chronological age and all-cause mortality are shown in purple.

Figure 2. a, Nested cross-validation mean absolute error (MAE) for all models with tuned hyperparameter values in the 10% hold-out test sets. CV = cross-validation. **b,** Heatmap of Pearson's correlation coefficient (*r*) between the predicted age values for all models. Estimates shown were multiplied by 100. **c,** Line plot showing the correlation between predicted age and chronological age for all models before (solid lines) and after (dotted lines) applying a statistical correction to the predicted age to remove the age bias (i.e., the systematic overestimation of age in young individuals and underestimation of age in older individuals). **d, e,** 2D density plots showing the correlation between predicted age derived from the Cubist rule-based regression model and chronological age before and after age bias correction. Observations beyond y-axis limits of 30 to 80 not shown. **f,** Mean absolute error for all models with tuned hyperparameter values calculated in the full sample after age bias correction. **g,** Density plot showing the distribution of MileAge delta (adj.) for all models. See Panel 1 for model abbreviations.

Figure 3. a, Associations between MileAge delta (adj.) and health indicators for all models. Models were adjusted for chronological age and sex. Reference group: individuals with a MileAge delta (adj.) smaller than one standard deviation below the mean. See Panel 1 for model abbreviations. **b,** Partial effect plots of generalised additive models of the association between health indicators and MileAge delta (adj.). Models were adjusted for chronological age and sex. The shaded areas correspond to 95% confidence intervals.

Figure 4. a, Kaplan-Meier plot showing survival probabilities for all-cause mortality by MileAge delta (adj.) derived from the Cubist rule-based regression model. Log-rank test *p*-value < 0.001. **b,** Hazard ratios and 95% confidence intervals from Cox proportional hazards models by MileAge delta (adj.) for all models. Models were adjusted for chronological age and sex. Age (in years) was used as the underlying time axis. Reference group: individuals with a MileAge delta (adj.) smaller than one standard deviation below the mean. See Panel 1 for model abbreviations. **c,** Density plot showing the distribution of MileAge delta (adj.) derived from the Cubist rule-based regression model. **d, e,** All-cause mortality rate by percentile of chronological age, MileAge (adj.) and MileAge delta (adj.) derived from the Cubist rule-based regression model. **f,** Histogram showing the distribution of MileAge delta (adj.) derived from the Cubist rule-based regression model, stratified by sex. **g, h,** Hazard ratios and 95% confidence intervals from Cox proportional hazards models for all-cause mortality by MileAge delta (adj.) derived from the Cubist rule-based regression model, stratified by self-rated health and chronological age group.

Figure 5. a, Hazard ratios (HR) and 95% confidence intervals from Cox proportional hazards models for all-cause mortality by MileAge delta (adj.), the frailty index, grip strength and telomere length. Models were adjusted for chronological age and sex. Age (in years) was used as the underlying time axis. Reference group: individuals with a score smaller than one standard deviation below the mean. **b,** C-index and 95% confidence intervals from Cox proportional hazards models for all-cause mortality for chronological age + sex (the base model) and for each ageing marker added separately to the base model. Time (in days) was used as the underlying time axis. **c,** Log(HRs) and 95% confidence intervals from Cox proportional hazards models for all-cause mortality. Models were adjusted for chronological age and sex. Age (in years) was used as the underlying time axis. Vertical lines indicate the median of the distribution which represents the reference for interpreting the estimates shown.